Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) EBITDA: 2010-2024

Historic EBITDA for Kura Oncology (KURA) over the last 14 years, with Dec 2024 value amounting to -$171.9 million.

  • Kura Oncology's EBITDA fell 51.44% to -$80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.9 million, marking a year-over-year change of. This contributed to the annual value of -$171.9 million for FY2024, which is 17.88% down from last year.
  • Latest data reveals that Kura Oncology reported EBITDA of -$171.9 million as of FY2024, which was down 17.88% from -$145.9 million recorded in FY2023.
  • Kura Oncology's EBITDA's 5-year high stood at -$89.9 million during FY2020, with a 5-year trough of -$171.9 million in FY2024.
  • For the 3-year period, Kura Oncology's EBITDA averaged around -$153.3 million, with its median value being -$145.9 million (2023).
  • Data for Kura Oncology's EBITDA shows a maximum YoY tumbled of 47.15% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Kura Oncology's EBITDA stood at -$89.9 million in 2020, then plummeted by 47.15% to -$132.3 million in 2021, then fell by 7.39% to -$142.1 million in 2022, then declined by 2.67% to -$145.9 million in 2023, then dropped by 17.88% to -$171.9 million in 2024.